New Delhi, Jan. 3 -- The impending patent expiry of semaglutide drugs across India, emerging markets and select regulated markets such as Canada and Brazil is expected to unlock a revenue opportunity exceeding Rs 50 billion for generic drug manufacturers over the next 12-15 months, according to an industry update by Systematix Institutional Research.

The opportunity is likely to be shared among 10-15 Indian and global generic players. For FY27, incremental revenues are estimated at Rs 10-20 billion from India's branded formulations market, around Rs 45 billion from regulated markets like Canada and Brazil, and Rs 5-10 billion from emerging markets.

While regulated markets could see a sharp near-term upside, the opportunity there may mod...